P. Vermersch

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
P Vermersch, P. Vermersch, Patrick Vermersch
Publication record
564 papers · 20,654 citations · H-index 66

PAPERS

Fatigue and Other Patient-Reported Outcomes in Patients With RRMS who Switched to Ocrelizumab: 4-Year Data From CASTING-LIBERTO (P6-3.010)
20231 citationsauthor #9
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
202311 citationsauthor #5
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
202367 citationsauthor #8
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
20234 citationsauthor #6
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
202330 citationsauthor #16
NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)
20230 citationsauthor #2
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
20230 citationsauthor #18
Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006)
20231 citationsauthor #13
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
202371 citationsauthor #7
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
20237 citationsauthor #8
Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study
20237 citationsauthor #12
MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial
20234 citationsauthor #1
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
20237 citationsauthor #14
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
202236 citationsauthor #9
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis
202246 citationsauthor #1
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
202235 citationsauthor #11
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis
202217 citationsauthor #12
043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis
20220 citationsauthor #4
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
20221 citationsauthor #1
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study
20226 citationsauthor #207
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis
202232 citationsauthor #1
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
202228 citationsauthor #3
Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis
20224 citationsauthor #11
Diagnosis and treatment of progressive multiple sclerosis: A position paper
202242 citationsauthor #3
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
202230 citationsauthor #8
143 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND
20220 citationsauthor #3
Early interventions to prevent lower urinary tract dysfunction after spinal cord injury: a systematic review
20221 citationsauthor #4
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets
202227 citationsauthor #13
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.
202238 citationsauthor #2
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
202210 citationsauthor #13
Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis.
20222 citationsauthor #2
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
20220 citationsauthor #8
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
202213 citationsauthor #17
024 CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets
20220 citationsauthor #1
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
20220 citationsauthor #7
118 Sustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients
20220 citationsauthor #4
016 Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension
20220 citationsauthor #5
015 Reduced risk of secondary progressive multiple sclerosis by treatment with clad- ribine tablets: CLARITY study analysis
20220 citationsauthor #1
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
202216 citationsauthor #5
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
20222 citationsauthor #9
Artificial intelligence extension of the OSCAR‐IB criteria
202138 citationsauthor #139
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
202168 citationsauthor #31
Role of the peripheral nervous system for an appropriate postural preparation during gait initiation in patients with a chronic inflammatory demyelinating polyneuropathy: A pilot study.
20213 citationsauthor #5
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
202118 citationsauthor #3
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
2021114 citationsauthor #3
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
202129 citationsauthor #5
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
202133 citationsauthor #8
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
202115 citationsauthor #4
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis
202123 citationsauthor #8
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
202111 citationsauthor #10
Untreated patients with multiple sclerosis: A study of French expert centers
202111 citationsauthor #11
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
20214 citationsauthor #18
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
202121 citationsauthor #3
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
202115 citationsauthor #8
Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study
202178 citationsauthor #8
Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database
20214 citationsauthor #5
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
202121 citationsauthor #1
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
202114 citationsauthor #3
Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
20217 citationsauthor #9
Asymptomatic optic nerve lesions
202032 citationsauthor #7
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS
202012 citationsauthor #11
Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data research.
202017 citationsauthor #9
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
202037 citationsauthor #116
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
20207 citationsauthor #4
Double‐blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate‐to‐severe relapses of multiple sclerosis
202010 citationsauthor #11
Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome
202037 citationsauthor #8
Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
202011 citationsauthor #1
Expert opinion on the use of cladribine tablets in clinical practice
202030 citationsauthor #6
Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)
20202 citationsauthor #1
Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
202014 citationsauthor #10
Improvements Across Functional Systems Are Maintained Regardless of Early VS Late Confirmed Disability Improvement: CARE-MS 6-Year Follow-Up
20200 citationsauthor #2
Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128)
20202 citationsauthor #5
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
202028 citationsauthor #1
Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up
20200 citationsauthor #13
BEST-MS: A Standardized and Prospective Study Comparing the Efficacy of Natalizumab versus Fingolimod in Active Relapsing Multiple Sclerosis. (769)
20200 citationsauthor #9
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment
202013 citationsauthor #1
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
202018 citationsauthor #6
Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study)
202011 citationsauthor #13
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130)
20205 citationsauthor #5
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
20208 citationsauthor #16
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort
202013 citationsauthor #9
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis
202065 citationsauthor #8
P34 Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies
20200 citationsauthor #7
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
20202 citationsauthor #4
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients.
202044 citationsauthor #5
Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years
20190 citationsauthor #1
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results)
20192 citationsauthor #1
Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study.
20194 citationsauthor #6
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
201920 citationsauthor #18
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
201950 citationsauthor #39
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
20199 citationsauthor #2
Alemtuzumab Controlled Clinical and MRI Outcomes and Slowed Brain Volume Loss in RRMS Patients: 8-Year Follow-up of CARE-MS II Patients (TOPAZ study)
20193 citationsauthor #12
Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study
20190 citationsauthor #3
Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension
20191 citationsauthor #5
Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
20197 citationsauthor #1
Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome
201940 citationsauthor #28
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
2019127 citationsauthor #6
Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study
20190 citationsauthor #3
Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study
20193 citationsauthor #1
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
201941 citationsauthor #10

TIMELINE

1987 6 citations

1989 4 citations

1990 5 citations

1991 16 citations

1992 48 citations

1993 1,002 citations

1994 84 citations

1995 102 citations

1996 224 citations

1997 87 citations

1998 108 citations

1999 1,032 citations

2000 204 citations

2001 836 citations

2002 372 citations

2003 464 citations

2004 1,664 citations

2005 601 citations

2006 210 citations

2007 1,182 citations

2008 1,260 citations

2009 383 citations

2010 1,307 citations

2011 995 citations

2012 407 citations

2013 385 citations

2014 1,177 citations

2015 634 citations

2016 990 citations

2017 1,001 citations

2018 1,859 citations

2019 471 citations

2020 418 citations

2021 527 citations

2022 386 citations

2023 210 citations

Unknown 0 citations

P. Vermersch

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT